Company / Cash & Equivalents
Edgewise Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$61.1M
FY2025
5-year range
$15.6M / $86.1M
FY2021-FY2025
Trend
+46.8%
vs FY2024
Sector context
#174 of 207
Health Care
What the data says
Edgewise Therapeutics, Inc.'s cash & equivalents of $61M is lower than 84% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 6 years, ranging from $16M in FY2021 to $105M in FY2020.
Based on SEC 10-K filings.
$61M in FY2025 with a 5-year CAGR of -10.2%.
Declined from $86M to $61M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +40.6%
- 5-Year CAGR
- -10.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 207This company $61.1M Sector average $669.5M
▼
-90.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -10.2%, indicating a declining trend.
- In FY2025, cash & equivalents increased 46.8% year-over-year.
- Ranks #174 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $61.1M | +46.8% |
| FY2024 | $41.7M | -51.6% |
| FY2023 | $86.1M | +291.5% |
| FY2022 | $22.0M | +41.3% |
| FY2021 | $15.6M | -85.2% |
| FY2020 | $104.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026